Chemistry:LGD-2226
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H9F9N2O |
| Molar mass | 392.225 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
LGD-2226 is an investigational selective androgen receptor modulator (SARM),[1] which is being developed for treatment of muscle wasting and osteoporosis.[2]
LGD-2226 is an orally active, potent and selective agonist for androgen receptors which was shown to have anabolic effects in both muscle and bone tissue, but with considerably less effects on prostate weight and luteinizing hormone levels than testosterone.[3][4]
Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar to anabolic steroids but with significantly less side effects. For this reason, SARMs have already been banned by the World Anti-Doping Agency since January 2008 despite no drugs from this class yet being in clinical use, and blood tests for all known SARMs are currently being developed,[5][6] including LGD-2226.[7]
References
- ↑ "Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator". Journal of Medicinal Chemistry 49 (21): 6143–6. October 2006. doi:10.1021/jm060792t. PMID 17034117.
- ↑ "Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)". Drug Discovery Today 12 (5–6): 241–8. March 2007. doi:10.1016/j.drudis.2007.01.003. PMID 17331889.
- ↑ "An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate". Endocrinology 148 (1): 363–73. January 2007. doi:10.1210/en.2006-0793. PMID 17023534.
- ↑ "Cell-specific activation of the human skeletal alpha-actin by androgens". Endocrinology 149 (3): 1103–12. March 2008. doi:10.1210/en.2007-0530. PMID 18063690.
- ↑ "Mass spectrometry of hydantoin-derived selective androgen receptor modulators". Journal of Mass Spectrometry 43 (5): 639–50. May 2008. doi:10.1002/jms.1364. PMID 18095383. Bibcode: 2008JMSp...43..639T.
- ↑ "Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS". Analytical and Bioanalytical Chemistry 391 (1): 251–61. May 2008. doi:10.1007/s00216-008-1882-6. PMID 18270691.
- ↑ "Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis". Rapid Communications in Mass Spectrometry 21 (21): 3477–86. 2007. doi:10.1002/rcm.3247. PMID 17985352. Bibcode: 2007RCMS...21.3477T.
 |  |
